Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 2,344 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer of Pancreas Clear all
Active, not recruiting Phase 2 Interventional

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

NCT05988918
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor, Pancreatic Neuroendocrine Carcinoma, Gastrointestinal Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Carcinoma, Neuroendocrine Prostate Carcinoma
Interventions
ESK981
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Ann Arbor, Michigan • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 4, 2026, 9:26 PM EDT
Recruiting Early Phase 1 Interventional

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

NCT04005690
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Interventions
Cobimetinib, Olaparib, Onvansertib, Azenosertib, Saruparib, Tremelimumab
Drug · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 4, 2026, 9:26 PM EDT
Completed No phase listed Observational

Ablation of Unresectable Locally Advanced Pancreatic Cancer With Irreversible Electroporation (IRE) System

NCT03614910
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Nanoknife Irreversible Electroporation
Device
Lead sponsor
Holy Name Medical Center, Inc.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 4, 2026, 9:26 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer

NCT02902484
View directory record Official record
Conditions
Cancer of Pancreas
Interventions
Nintedanib
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 4, 2026, 9:26 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer

NCT00577889
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
gemcitabine hydrochloride, tanespimycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 4, 2026, 9:26 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

NCT06179160
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX, FOLFOX, FOLFIRI, INCA33890
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 4, 2026, 9:26 PM EDT
Completed Phase 2 Interventional

The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid

NCT00001191
View directory record Official record
Conditions
Gastrinoma, Zollinger Ellison Syndrome
Interventions
Pantoprazole, Omeprazole
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1983 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 4, 2026, 9:26 PM EDT
Completed Not applicable Interventional

Whipple Protein Study

NCT04306874
View directory record Official record
Conditions
Pancreatic Cancer, Malnutrition
Interventions
Ensure Max Protein
Dietary Supplement
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 4, 2026, 9:26 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

NCT02047474
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Interventions
oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
9
States / cities
Fairfield, Connecticut • Guilford, Connecticut • Hartford, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 4, 2026, 9:26 PM EDT
Completed Phase 1 Interventional Results available

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

NCT01761240
View directory record Official record
Conditions
Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Interventions
MORAb-066
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 4, 2026, 9:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers

NCT01528774
View directory record Official record
Conditions
Melanoma
Interventions
Blood Draw
Other
Lead sponsor
Wolfram Samlowski
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 4, 2026, 9:26 PM EDT
Completed No phase listed Observational

Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery

NCT00900016
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
protein expression analysis, western blotting, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 4, 2026, 9:26 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

NCT04130516
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody
Drug · Biological
Lead sponsor
Linnaeus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 4, 2026, 9:26 PM EDT
Suspended Phase 2 Interventional

A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer

NCT00536770
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
placebo + gemcitabine + erlotinib, Placebo + gemcitabine, calcitriol + gemcitabine, calcitriol + gemcitabine + erlotinib
Drug
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 4, 2026, 9:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal Adenocarcinoma

NCT02775786
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
MRIs with and without intravenous contrast (up to 2)
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 4, 2026, 9:26 PM EDT
Completed Phase 2 Interventional Results available

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

NCT04896073
View directory record Official record
Conditions
Adenosquamous Carcinoma of the Pancreas
Interventions
Minnelide, ECG, CT/MRI, Tumor Biopsy
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 4, 2026, 9:26 PM EDT
Completed Phase 4 Interventional

Prospective Study of Celiac Block Injection: 1 vs. 2

NCT00583479
View directory record Official record
Conditions
Chronic Pancreatitis, Pancreatic Cancer
Interventions
one injection into the celiac ganglion, two injections into the celiac ganglion
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Oct 4, 2026, 9:26 PM EDT
Completed Not applicable Interventional Results available

Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer

NCT01015820
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
EGD with EUS, 4D-ELF
Procedure · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 4, 2026, 9:26 PM EDT
Recruiting No phase listed Observational

Registry of Patients Undergoing Endoscopic Management of Pancreatic Fluid Collections

NCT06179459
View directory record Official record
Conditions
Acute Pancreatitis, Pancreatic Pseudocyst, Pancreatic Necrosis
Interventions
Endoscopic management of pancreatic fluid collections
Procedure
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 4, 2026, 9:26 PM EDT
Terminated Phase 1 Interventional

Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer

NCT02548169
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
DC Vaccine + Standard of Care Chemotherapy
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 4, 2026, 9:26 PM EDT
Active, not recruiting No phase listed Observational

Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer

NCT01580241
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 4, 2026, 9:26 PM EDT
Completed Phase 1 Interventional

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

NCT00667641
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, paclitaxel
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 10, 2011 · Synced Oct 4, 2026, 9:26 PM EDT
Terminated Phase 1 Interventional

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

NCT06130254
View directory record Official record
Conditions
Advanced Solid Tumor, Non-small Cell Lung Cancers
Interventions
Adagrasib, Olaparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 4, 2026, 9:26 PM EDT
Terminated Not applicable Interventional Results available

"Answers in Hours" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile Duct Cultures

NCT05523154
View directory record Official record
Conditions
Benign Pancreatic Neoplasm, Malignant Pancreatic Neoplasm
Interventions
Biospecimen Collection, Laboratory Procedure, Nanopore Sequencing
Procedure · Other · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 4, 2026, 9:26 PM EDT